Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-02-24

    Virtual Booth

    Contact Supplier

    Menu

    Benralizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AstraZeneca asthma drug more effective during attack than steroids
    AstraZeneca asthma drug more effective during attack than steroids

    30 Nov 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-asthma-drug-more-effective-during-attack-than-steroids-study-finds-2024-11-27/

    REUTERS
    30 Nov 2024
    Share Share
    Fasenra approved in the EU for eosinophilic granulomatosis (EGPA)
    Fasenra approved in the EU for eosinophilic granulomatosis (EGPA)

    29 Oct 2024

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis.html

    PRESS RELEASE
    29 Oct 2024
    Share Share
    AstraZeneca's Fasenra Approved in the US for Rare Blood Vessel Disease
    AstraZeneca's Fasenra Approved in the US for Rare Blood Vessel Disease

    19 Sep 2024

    // CONTRACTPHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-09-18/astrazenecas-fasenra-approved-in-the-us-for-rare-blood-vessel-disease/?widget=listSection

    CONTRACTPHARMA
    19 Sep 2024
    Share Share
    AstraZeneca`s Biologic Fasenra (Benralizumab) Receives Approvals In U.S
    AstraZeneca`s Biologic Fasenra (Benralizumab) Receives Approvals In U.S

    17 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070

    FDA
    17 Sep 2024
    Share Share
    FASENRA approved for treatment of children aged 6 to 11 with severe asthma
    FASENRA approved for treatment of children aged 6 to 11 with severe asthma

    12 Apr 2024

    // PRESS RELEASE

    https://www.astrazeneca-us.com/media/press-releases/2024/fasenra-approved-for-treatment-of-children-aged-6-to-11-with-severe-asthma.html

    PRESS RELEASE
    12 Apr 2024
    Share Share
    AstraZeneca steps up to show Fasenra helping patients step out
    AstraZeneca steps up to show Fasenra helping patients step out

    25 Mar 2024

    // Nick Paul Taylor FIERCE PHARMA

    https://www.fiercepharma.com/marketing/astrazeneca-steps-show-fasenra-helping-patients-step-out-ad-push-asthma-drug

    Nick Paul Taylor FIERCE PHARMA
    25 Mar 2024
    Share Share